FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Sanofi breaks ground on $477M vax plant

Sanofi-Aventis is still testing its new Dengue fever jab, but it's already broken ground on a massive new manufacturing plant in France that will churn out a huge supply of the vaccine.

Sanofi is investing $477 million--its most expensive single industrial project--in the new facility north of Lyon. And if it stays on schedule, the plant will be ready to start making the new vaccine in 2013. Sanofi CEO Chris Viehbacher (photo) says that the new vaccine, once approved, has clear potential for earning more than a billion euros a year.

"It's hard to give a precise estimate, but I wouldn't be investing 350 million euros if there wasn't a strong chance that this is the biggest vaccine ever," Viehbacher said. There are 50 million new Dengue fever infections every year.

- read the story from BusinessWeek

Related Articles:
Sanofi advances new vaccine for dengue
Sanofi launches new trial for dengue fever
Brazilian Dengue outbreak highlights vaccine need


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Dengue fever   manufacturing   Sanofi-Aventis  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.